Opko Health, INC Form 4 insider transactions

Adam Logal, Sr. Vice President, CFO of Opko Health, Inc., reported a transaction in 53,266 shares of common stock on July 24, 2026.

Steven D Rubin, Executive VP-Administration and a Director of Opko Health, Inc., reported a transaction in 53,266 shares of common stock on July 24, 2026.

OPKO Health Director John Paganelli acquired 10,000 shares of common stock at $1.135 per share, increasing his direct beneficial ownership.

OPKO Health Director Subbarao V. Uppaluri acquired 50,000 stock options with an exercise price of $1.17, exercisable from March 2027.

Phillip Frost, CEO and Chairman of OPKO Health, reported the acquisition of 580,000 shares of common stock through indirect holdings on November 21, 2025.

Phillip Frost, CEO and Chairman of OPKO Health, acquired 570,000 shares of common stock through trusts, signaling increased insider confidence.

OPKO Health's CEO and Chairman, Phillip Frost, M.D., along with affiliated trusts, acquired 580,000 shares of common stock for approximately $750,000.

OPKO Health's CEO and Chairman, Phillip Frost, M.D., increased his beneficial ownership by purchasing over 530,000 shares of common stock through various trusts.

OPKO Health's CEO and Chairman, Dr. Phillip Frost, acquired 150,000 shares of common stock for approximately $213,435 on October 31, 2025.

OPKO Health's CEO and Chairman, Phillip Frost, reported a gift of 440,000 common shares through an indirect holding, effective August 18, 2025.

OPKO Health's CEO and Chairman, Phillip Frost, disclosed a pre-planned acquisition and a larger disposition of company common stock set for August 8, 2025, under a Rule 10b5-1(c) plan.

OPKO Health's CEO and Chairman, Phillip Frost, was granted 500,000 stock options with an exercise price of $1.31, vesting over four years.

OPKO Health, Inc. has granted 500,000 stock options to Dr. Jane Hsiao, its Vice Chairman and Chief Technology Officer, with an exercise price of $1.31 per share, vesting over four years.

OPKO Health, Inc. has granted 500,000 stock options to Elias A. Zerhouni, its Vice Chairman and President, with an exercise price of $1.31 per share, vesting over four years.

Steven D. Rubin, Executive VP-Administration and Director at OPKO Health, Inc., was granted 437,500 stock options with an exercise price of $1.31, vesting over four years.

OPKO Health's Senior Vice President and Chief Financial Officer, Adam Logal, was granted 437,500 stock options as part of his compensation.

OPKO Health, Inc. has granted its Chief Innovation Officer and Director, Gary J. Nabel, 437,500 stock options with an exercise price of $1.31, vesting over four equal annual installments.

Director Richard M. Krasno acquired 30,000 stock options in OPKO Health, Inc. on April 23, 2025.

Prem A. Lachman, a director of OPKO Health, Inc., reported the acquisition of 30,000 stock options on April 23, 2025.

Director Roger Medel acquired 30,000 stock options in OPKO Health, Inc. on April 23, 2025.

John A. Paganelli, a director at OPKO Health, Inc., acquired 30,000 stock options on April 23, 2025, according to a recent SEC filing.

Richard C. Pfenniger Jr., a director of OPKO Health, Inc., acquired 60,000 stock options on April 23, 2025.

Director Yu Alice Lin-Tsing acquired 30,000 stock options in OPKO Health, Inc. on April 23, 2025.

OPKO Health's CEO, Phillip Frost, recently purchased 125,000 shares of the company's common stock at an average price of $1.3577 per share.

Phillip Frost, CEO and Chairman of OPKO Health, Inc., purchased 125,000 shares of common stock at a weighted average price of $1.4772 on April 8, 2025.

Phillip Frost, CEO and Chairman of OPKO Health, reports the acquisition of 100,000 shares of common stock at a weighted average price of $1.6485.

OPKO Health's CEO, Phillip Frost, purchased 150,000 shares of common stock at an average price of $1.6959 on March 28, 2025.

OPKO Health's CEO, Phillip Frost, purchased 200,000 shares of common stock at an average price of $1.7391 on March 17, 2025.

Phillip Frost, CEO and Chairman of OPKO Health, and Frost Gamma Investments Trust report a transaction involving 3.75% Convertible Notes due 2029 and common stock.

Phillip Frost, along with Frost Gamma Investments Trust, reports transactions involving OPKO Health's convertible notes and common stock.